Macquarie Group LTD Vertex Pharmaceuticals Inc Transaction History

Macquarie Group LTD

$85.1 Billion
Q2 2024

A detailed history of Macquarie Group LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Macquarie Group LTD holds 335,745 shares of VRTX stock, worth $173 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares

335,745

Previous 372,241 9.8%

Holding current value

$173 Million

Previous $156 Million 1.14%

% of portfolio

0.18%

Previous 0.18%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$392.81 - $485.53 $14.3 Million - $17.7 Million	-36,496 Reduced 9.8%	335,745 $157 Million
Q1 2024 May 14, 2024	SELL	$407.69 - $446.08 $10.2 Million - $11.2 Million	-25,053 Reduced 6.31%	372,241 $156 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $114 Million - $137 Million	-333,639 Reduced 45.65%	397,294 $162 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $5.58 Million - $5.98 Million	16,498 Added 2.31%	730,933 $254 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $16.3 Million - $18.3 Million	-51,939 Reduced 6.78%	714,435 $251 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $26.3 Million - $30 Million	-92,926 Reduced 10.81%	766,374 $241 Million
Q4 2022 Feb 21, 2023	SELL	$285.76 - $321.48 $10.9 Million - $12.2 Million	-38,008 Reduced 4.24%	859,300 $248 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $9.82 Million - $11 Million	-35,871 Reduced 3.84%	897,308 $260 Million
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $153 Million - $191 Million	652,321 Added 232.26%	933,179 $263 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $5.18 Million - $6.11 Million	-23,399 Reduced 7.69%	280,858 $73.3 Million
Q4 2021 Feb 11, 2022	SELL	$177.01 - $223.45 $185 Million - $234 Million	-1,046,258 Reduced 77.47%	304,257 $66.8 Million
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $48.3 Million - $54 Million	-266,259 Reduced 16.47%	1,350,515 $245 Million
Q2 2021 Aug 13, 2021	BUY	$187.49 - $221.1 $275 Million - $324 Million	1,466,287 Added 974.36%	1,616,774 $326 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $2.98 Million - $3.47 Million	14,384 Added 10.57%	150,487 $32.3 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $1.19 Million - $1.58 Million	5,739 Added 4.4%	136,103 $32.2 Million
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $4.97 Million - $5.89 Million	19,437 Added 17.52%	130,364 $35.5 Million
Q2 2020 Aug 11, 2020	BUY	$225.48 - $295.8 $407,442 - $534,510	1,807 Added 1.66%	110,927 $32.2 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $3 Million - $3.72 Million	-15,009 Reduced 12.09%	109,120 $26 Million
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $2.59 Million - $3.47 Million	-15,512 Reduced 11.11%	124,129 $27.2 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $507,001 - $570,624	3,050 Added 2.23%	139,641 $23.7 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $3.16 Million - $3.66 Million	-19,219 Reduced 12.33%	136,591 $25 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $579,604 - $689,238	-3,540 Reduced 2.22%	155,810 $28.7 Million
Q4 2018 Feb 15, 2019	BUY	$151.91 - $192.21 $867,861 - $1.1 Million	5,713 Added 3.72%	159,350 $26.4 Million
Q3 2018 Nov 15, 2018	SELL	$167.73 - $192.74 $2.26 Million - $2.6 Million	-13,490 Reduced 8.07%	153,637 $29.6 Million
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $1.98 Million - $2.31 Million	-13,605 Reduced 7.53%	167,127 $28.4 Million
Q1 2018 May 11, 2018	BUY	$151.6 - $177.13 $1.89 Million - $2.21 Million	12,459 Added 7.4%	180,732 $29.5 Million
Q4 2017 Feb 15, 2018	SELL	$137.28 - $155.55 $7.69 Million - $8.71 Million	-56,001 Reduced 24.97%	168,273 $24.9 Million
Q3 2017 Nov 08, 2017	BUY	$148.13 - $162.24 $33.2 Million - $36.4 Million	224,274	224,274 $34.1 Million

Others Institutions Holding VRTX

# of Institutions

1,717

Shares Held

226M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $133B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Vertex Pharmaceuticals Inc Transaction History